Clinical Trials Logo

Metastatic Breast Carcinoma clinical trials

View clinical trials related to Metastatic Breast Carcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04906369 Suspended - Clinical trials for Anatomic Stage IV Breast Cancer AJCC v8

Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring

Start date: November 16, 2020
Phase:
Study type: Observational

This study evaluates if blood tests can detect changes in disease status during treatment for stage IV breast cancer. Information from this study may help researchers learn more about metastatic breast cancer and how to optimize treatment.

NCT ID: NCT03737695 Suspended - Clinical trials for Anatomic Stage IV Breast Cancer AJCC v8

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

Start date: September 16, 2019
Phase:
Study type: Observational

This trial collects clinical information and tissue and blood samples from patients with breast cancer that has come back or is stage IV. Collecting clinical information and biospecimen samples to create a registry may help doctors better understand the mechanism of tumor spread and determine why people respond differently to specific cancer treatments.

NCT ID: NCT03432741 Suspended - Clinical trials for Recurrent Breast Carcinoma

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Start date: March 27, 2018
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.